N/A N=242 The IPED (Investigation of Palpitations in the ED) Study
Presyncope · Arrhythmias, Cardiac · Tachycardia, Supraventricular
Primary: Number of Participants With Symptomatic Rhythm Detection up to 90 Days — 69; 11 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 3 N=393 Long-Term Safety and Tolerability of Mesalamine Pellets in Participants With Ulcerative Colitis in Remission
Ulcerative Colitis
Primary: Number of Participants With Treatment-Emergent Adverse Events (TEAEs) — 280 Participants
Phase 3 N=70 Study to Evaluate Immunogenicity and Safety of GSK Biologicals' Herpes Zoster Subunit (HZ/su) Vaccine at 9 and 10 Years After Vaccine Administration and Assessment of Re-vaccination With 2 Additional Doses at 10 Years After Initial Vaccination, in Healthy Subjects Aged 60 Years of Age(YOA) and Older
Herpes Zoster
Primary: Anti-glycoprotein (gE) Specific Antibody (Ab) Concentrations — 9122.9 mIU/mL
N/A N=146 A Prospective Non-interventional Multicenter Study to Evaluate the Effectiveness of Adalimumab in Korean Patients With Ulcerative Colitis (UC) and Identify Potential Predictors of Clinical Response in Routine Clinical Practice
Ulcerative Colitis
Primary: Percentage of Participants Who Were Week 8 Responders With Durable Clinical Response at Week 56 — 53.95 percentage of participants
N/A N=251 A Natural History of the Progression of Stargardt Disease: Retrospective and Prospective Studies
Stargardt Disease
Primary: Yearly Progression Rate of Atrophic Lesions Using Fundus Autofluorescence (FAF) Images — 0.35; 0.64 mm^2/year
N/A N=6 Clinical Assessment of a Closed-loop System With Glucagon, Exercise and Mixed Meals
Type 1 Diabetes
Primary: Percentage of Time in Target Range Over 24 Hour — 2; 4.7; 1.3 percentage of time
N/A N=44 Effect of Fermentable Carbohydrate on Glucose Homeostasis
Prediabetes
Primary: Glycaemic Control — -0.23; 0.44 mmol//l — p=0.005
N/A N=671 Treatment Convenience in Patients Treated With Dabigatran for Stroke Prophylaxis in Atrial Fibrillation (SPAF)
Atrial Fibrillation
Primary: Mean of Perception of Anticoagulant Treatment Questionnaire 2 (PACT-Q2) Scores at Second Assessment Compared to Baseline Assessment — 59.86; 80.96; 49.15; 69.35 Units on…
Phase 2 N=51 Safety and Tolerability, Pharmacokinetics (PK), Pharmacodynamics (PD) and Efficacy of Repeat Doses of GSK2982772 in Subjects With Moderate to Severe Rheumatoid Arthritis (RA)
Arthritis, Rheumatoid
Primary: Number of Participants With Non-serious Adverse Events (nSAEs) and Serious Adverse Events (SAEs) as a Measure of Safety and Tolerability — 3; 10; 3; 16 Participants
Phase 1 N=12 A Safety and Pharmacokinetic (PK) Study of GSK2982772 in Healthy Subjects
Autoimmune Diseases
Primary: Number of Subjects With Adverse Events (AEs) and Serious AEs (SAEs): Part A — 3; 6; 4; 7 Participants
N/A N=24 Laser-Assisted Regenerative Surgical Therapy for Peri-implantitis
Peri-Implantitis
Primary: Change in Periodontal Probing Depths (PD) — 1.85; 2.65 millimeters
N/A N=41 Effect of Heat Exposure on Cognition in Persons With Tetraplegia
Tetraplegia · Hypothermia · Mild Cognitive Impairment
Primary: Change in Core Body Temperature From Baseline to 120 Minutes Post Warm Challenge — 0.59; -0.05 degrees Centigrade
N/A N=312 Special Drug Use Surveillance of Leuprorelin for Injection Kit 22.5 mg in "Premenopausal Breast Cancer"
Premenopausal Breast Cancer
Primary: Percentage of Participants Who Had One or More Adverse Events — 6.45 Percentage of Participants
Phase 3 N=360 Safety and Efficacy of SPIL1033 in Subjects With Type 2 Diabetes Mellitus
Type 2 Diabetes Mellitus
Primary: Change From Baseline to End of Study in Hemoglobin A1c (HbA1c) — -0.227; -0.227 percentage of hemoglobin A1c (HbA1c)
Phase 4 N=12 Study to Compare the Awakening Threshold Effects of Belsomra 10 mg and 20 mg to Placebo in Non-elderly Insomniacs
Insomnia
Primary: Auditory Awakening Threshold — 74.17; 83.75; 79.17 decibels (db)